Business Insights, June 2011, Pages: 187
of the cancer diagnostics market including: breast, colorectal, prostate, lung, and renal cancer.
Highlights
Advances in genomics, proteomics, molecular imaging, and other new technologies are leading
Jain PharmaBiotech, May 2012, Pages: 1037
Table 8-7: Methods for comparison of gene-expression profilling in tumor specimens
Table 8-8: Impact of in vivo molecular imaging of cancer on oncology practice
Table 8-9: Molecular diagnostic tests
Bioseeker, Dec 2011, Pages: 1617
strategies, and assesses them in 69 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the apoptotic drug pipeline in oncology and discern the level of competition
Jain PharmaBiotech, May 2012, Pages: 873
Anatomy Project
Molecular profiling of cancerCancerGenome Atlas
Cancer Genetic Markers of Susceptibility Project
Oncology Biomarker Qualification Initiative
Role of NCI in cancer biomarker
TriMark Publications, July 2011, Pages: 214
Diagnostics
2.2 Impact of the Human Genome Project on Molecular Diagnostics
2.3 Considerations for Molecular and Clinical Diagnostics
2.4 Molecular Diagnostics in the Post-Genomic Era
2.5 Advances
Business Insights, Oct 2009, Pages: 141
Innovations in Oncology Diagnostics: Technological Advances, Growth Opportunities and Future Market Outlook Despite public policy measures to prevent cancer, such as tobacco control and vaccination
Decision Resources, Inc., Dec 2008, Pages: 33
Matrix Metalloproteinases-9
Biomarker-Based Diagnostics in Oncology
ER/PR Status
Overexpression of HER2
KRAS Mutations
Consortia for AdvancingCancer Biomarker Research
Oncology Biomarker Qualifi
DeciBio, Feb 2012, Pages: 117
for breast cancer, Factor V Leiden for coagulation). MDx tests continue to be the fastest growing segment within the IVD space, driven by high sensitivity, fast turnaround time, easy workflow and relatively
Bioseeker, Nov 2011, Pages: 906
.2.39 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
6.2.40 Ubiquitin-specific Protease Activity Targets
6.2.41 Other Targets
6.3 The CancerGenome Project and Targets of Peptide Drugs in Oncology
Bioseeker, Sep 2010, Pages: 1227
Drug Pipeline in Oncology and Competitive Fall-Out
Table 159: Adherex's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out
Table 160: AdvancedCancer Therapeutics
Arrowhead Publishers, May 2010, Pages: 261
PERSONALIZED MEDICINE THERAPEUTICS
10.1 INTRODUCTION TO PERSONALIZED MEDICINE THERAPEUTICS
10.2 ONCOLOGY PERSONALIZED MEDICINE THERAPEUTICS
10.3 LUNG CANCER
10.3.1 OSI Pharmaceuticals/ Roche’s Tarceva
Decision Resources, Inc., Dec 2009, Pages: 38
Dealmaking and Industry Outlook: Targeted Cancer Therapies Effective therapy resulting in a cure is still the greatest unmet need in oncology. The major driver behind oncology markets now
Bioseeker, Nov 2009, Pages: 803
.2.49 Other Drug Targets
6.3 The CancerGenome Project and Apoptotic Therapeutic Targets in Oncology
6.3.1 Apoptotic Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of
Somatic
Bioseeker, March 2012, Pages: 1103
of pancreatic cancer drugs belongs to Pfizer, Hoffmann-La Roche, Novartis and AstraZeneca.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes
TriMark Publications, Sep 2010, Pages: 1846
and services. The report will include detailed market analyses and discussions of industry trends in order to assess the impact of genomics on the current and emerging pharmaceutical and diagnostic markets
Business Insights, Sep 2006, Pages: 126
driven by miniaturization and advances in genomics will enhance the role of diagnostics in the healthcare market, allowing more tests to be performed at the point-of-care and facilitating the shift towards
Bioseeker, March 2011, Pages: 1056
Summary
2 About Cancer Highlights™
2.1 Cancer Focus Areas
2.2 Subscribe Today and Start Saving
2.2.1 Type of License
2.3 BioSeeker Group’s Oncology Team
3 Methodology
3.1 Cancer
Decision Resources, Inc., Dec 2008, Pages: 39
biomarker—determines response to certain therapies for select cancers. What is the future impact of this safety biomarker and other key markers on drugs and diagnostics in development market?
Scope
